Moderna Inc [NASDAQ: MRNA] jumped around 3.18 points on Wednesday, while shares priced at $110.59 at the close of the session, up 2.96%. The company report on March 27, 2024 at 6:30 AM that Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials.
Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV.
Compared to the average trading volume of 4.45M shares, MRNA reached a trading volume of 4569220 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Moderna Inc [MRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $129.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.27. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
HSBC Securities have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Reduce, with their previous recommendation back on February 26, 2024. The new note on the price target was released on January 02, 2024, representing the official price target for Moderna Inc stock. Previously, the target price had yet another raise to $82, while Canaccord Genuity analysts kept a Hold rating on MRNA stock. On November 03, 2023, analysts decreased their price target for MRNA shares from 89 to 69.
The Average True Range (ATR) for Moderna Inc is set at 4.75, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 6.18. The Price to Book ratio for the last quarter was 3.05, with the Price to Cash per share for the same quarter was set at 22.52.
How has MRNA stock performed recently?
Moderna Inc [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.29. With this latest performance, MRNA shares gained by 14.96% in over the last four-week period, additionally plugging by 12.71% over the last 6 months – not to mention a drop of -25.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 61.75, with the RSI for the last a single of trading hit 64.65, and the three-weeks RSI is set at 59.58 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 99.03, while it was recorded at 107.58 for the last single week of trading, and 100.48 for the last 200 days.
Moderna Inc [MRNA]: Deeper insight into the fundamentals
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.36 and a Current Ratio set at 3.42.
Earnings analysis for Moderna Inc [MRNA]
With the latest financial reports released by the company, Moderna Inc posted 0.19/share EPS, while the average EPS was predicted by analysts to be reported at -1.77/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 110.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA.
Insider trade positions for Moderna Inc [MRNA]
The top three institutional holders of MRNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in MRNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in MRNA stock with ownership which is approximately 5.8325%.
